These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 24488441)

  • 1. Driving CAR-based T-cell therapy to success.
    Jena B; Moyes JS; Huls H; Cooper LJ
    Curr Hematol Malig Rep; 2014 Mar; 9(1):50-6. PubMed ID: 24488441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
    Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
    Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
    Kenderian SS; Ruella M; Gill S; Kalos M
    Cancer Res; 2014 Nov; 74(22):6383-9. PubMed ID: 25371415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
    Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
    Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Briefing on Investigational Chimeric Antigen Receptor T-Cell Immunotherapies in Pediatric Neoplasms.
    Stawicki B; Schacher T; Dushenkov A; Jungsuwadee P
    J Pharm Pract; 2024 Dec; 37(6):1346-1360. PubMed ID: 38718427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
    Sabatino M; Hu J; Sommariva M; Gautam S; Fellowes V; Hocker JD; Dougherty S; Qin H; Klebanoff CA; Fry TJ; Gress RE; Kochenderfer JN; Stroncek DF; Ji Y; Gattinoni L
    Blood; 2016 Jul; 128(4):519-28. PubMed ID: 27226436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CAR T-cell therapy: Balance of efficacy and safety].
    Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
    Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor-modified T cells: CD19 and the road beyond.
    Salter AI; Pont MJ; Riddell SR
    Blood; 2018 Jun; 131(24):2621-2629. PubMed ID: 29728402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
    Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
    Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.
    Dai H; Wang Y; Lu X; Han W
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26819347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
    Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
    Firor AE; Jares A; Ma Y
    Exp Biol Med (Maywood); 2015 Aug; 240(8):1087-98. PubMed ID: 25956686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
    Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y
    Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.